Pirtobrutinib in Covalent BTK Inhibitor Pre-Treated Mantle Cell Lymphoma: Updated Results and Subgroup Analysis from the Phase 1/2 BRUIN Study With >3 Years Follow-Up from Start of Enrollment

被引：0

作者：

Wang, Michael L. ^{[1
]}

Shah, Nirav N. ^{[2
]}

Jurczak, Wojciech ^{[3
,6
]}

Zinzani, Pier Luigi ^{[4
,5
]}

Eyre, Toby A.

Cheah, Chan Y. ^{[7
,8
,9
]}

Ujjani, Chaitra S. ^{[10
]}

Izutsu, Koji ^{[11
]}

Ma, Shuo ^{[12
]}

Flinn, Ian ^{[13
]}

Alencar, Alvaro J. ^{[14
]}

Lewis, David ^{[15
]}

Patel, Krish ^{[16
]}

Maddocks, Kami ^{[17
]}

Wang, Yucai ^{[18
]}

Munir, Talha ^{[19
]}

Zelenetz, Andrew D. ^{[20
]}

Balbas, Minna ^{[21
]}

Tsai, Donald E. ^{[21
]}

Wang, Chunxiao ^{[22
]}

机构：

[1] MD Anderson Canc Ctr, Houston, TX USA

[2] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[3] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland

[4] IRCCS Azienda Osped Univ Bologna Ist Ematol, Seragnoli, Italy

[5] Univ Bologna, Dipartimento Med Specialist Diag & Sperimentale, Bologna, Italy

[6] Oxford Univ Hosp NHS Fdn Trust, Churchill Canc Ctr, Oxford, England

[7] Linear Clin Res, Perth, WA, Australia

[8] Sir Charles Gairdner Hosp, Perth, WA, Australia

[9] Univ Western Australia, Med Sch, Perth, WA, Australia

[10] Univ Washington, Fred Hutchinson Canc Res Ctr, Washington, DC USA

[11] Natl Canc Ctr, Dept Hematol, Tokyo, Japan

[12] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA

[13] Sarah Cannon Res Inst & Tennessee Oncol, Nashville, TN USA

[14] Sylvester Comprehens Canc Ctr, Miami, FL USA

[15] Plymouth Hosp NHS Trust Derriford Hosp, Plymouth, Devon, England

[16] Swedish Canc Inst, Ctr Blood Disorders & Cellular Therapy, Seattle, WA USA

[17] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[18] Mayo Clin, Div Hematol, Rochester, MN USA

[19] St James Univ Hosp, Dept Haematol, Leeds, W Yorkshire, England

[20] Memorial Sloan Kettering Canc Ctr, New York, NY USA

[21] Loxo Lilly, Indianapolis, IN USA

[22] Eli Lilly & Co, Indianapolis, IN USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

MCL; BTK-inhibitor; pirtobrutinib; TP53; mutation;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MCL-155

引用

页码：S459 / S459

页数：1

共 50 条

[11] Pirtobrutinib, a Non-Covalent (reversible) BTK Inhibitor, in Mantle Cell Lymphoma Patients Previously Treated with a Covalent BTK Inhibitor: Results from a China Phase 2 Study
Song, Yuqin
Yi, Shuhua
Yang, Haiyan
Feng, Ru
Huang, Huiqiang
Zhang, Qingyuan
Liu, Yanyan
Guo, Ye
Zhang, Huilai
Zhang, Liling
Qian, Yijiao
Zhu, JianKun
Zhu, Jun
BLOOD, 2023, 142
[12] Pirtobrutinib in Heavily Pre-Treated Richter Transformation: Updated Efficacy and Safety Results with 18-month Median Survival Follow-up from the Phase 1/2 BRUIN Study
Wierda, William G.
Shah, Nirav N.
Cheah, Chan Y.
Lewis, David
Hoffman, Marc S.
Coombs, Catherine C.
Lamanna, Nicole
Shuo, M. A.
Jagadeesh, Deepa
Munir, Talha
Wang, Yucai
Eyre, Toby A.
Rhodes, Joanna
Mckinney, Matthew
Lech-Maranda, Ewa
Tam, Constantine S.
Jurczak, Wojciech
Izutsu, Koji
Alencar, Alvaro
Patel, Manish R.
Seymour, John F.
Woyach, Jennifer
Roeker, Lindsey E.
Thompson, Philip A.
Abada, Paolo
Ho, Caleb
Marella, Narasimha
Wang, Chunxiao
Ruppert, Amy S.
Nair, Binoj
Liu, Hui
Tsai, Donald E.
Ghia, Paolo
Al-Sawaf, Othman
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 120 - 121
[13] Pirtobrutinib, A Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study
Coombs, Catherine C.
Pagel, John M.
Shah, Nirav N.
Lamanna, Nicole
Munir, Talha
Lech-Maranda, Ewa
Eyre, Toby A.
Woyach, Jennifer A.
Wierda, William G.
Cheah, Chan Y.
Cohen, Jonathon B.
Roeker, Lindsey E.
Patel, Manish R.
Fakhri, Bita
Barve, Minal A.
Tam, Constantine S.
Lewis, David
Gerson, James N.
Alencar, Alvaro
Ujjani, Chaitra
Flinn, Ian
Sundaram, Suchitra
Ma, Shuo
Jagadeesh, Deepa
Rhodes, Joanna
Taylor, Justin
Abdel-Wahab, Omar
Ghia, Paolo
Schuster, Stephen J.
Wang, Denise
Nair, Binoj
Zhu, Edward
Tsai, Donald E.
Davids, Matthew S.
Brown, Jennifer R.
Jurczak, Wojciech
Mato, Anthony R.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S268 - S269
[14] Pirtobrutinib, A Highly Selective, Non-covalent (Reversible) BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study
Mato, Anthony
Pagel, John
Coombs, Catherine
Shah, Nirav
Lamanna, Nicole
Munir, Talha
Lech-Maranda, Ewa
Eyre, Toby
Woyach, Jennifer
Wierda, William
Cheah, Chan
Cohen, Johnathan
Roeker, Lindsey
Patel, Manish
Fakhri, Bita
Barve, Minal
Tam, Constantine
Lewis, David
Gerson, James
Alencar, Alvaro
Ujjani, Chaitra
Flinn, Ian
Sundaram, Suchitra
Ma, Shuo
Jagadeesh, Deepa
Rhodes, Joanna
Taylor, Justin
Abdel-Wahab, Omar
Ghia, Paolo
Schuster, Stephen
Wang, Denise
Nair, Binoj
Zhu, Edward
Tsai, Donald
Davids, Matthew
Brown, Jennifer
Jurczak, Wojciech
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 97 - 101
[15] Genomic evolution and resistance to pirtobrutinib in covalent BTK-inhibitor pre-treated chronic lymphocytic leukemia patients: results from the phase I/II BRUIN Study
Brown, Jennifer
Desikan, Sai Prasad
Nguyen, Bastien
Won, Helen
Tantawy, Shady I.
McNeely, Samuel C.
Marella, Narasimha
Ebata, Kevin
Woyach, Jennifer
Patel, Krish
Tam, Constantine S.
Eyre, Toby A.
Cheah, Chan Y.
Shah, Nirav
Ghia, Paolo
Jurczak, Wojciech
Balbas, Minna
Nair, Binoj
Abada, Paolo
Wang, Chunxiao
Wang, Denise
Mato, Anthony
Gandhi, Varsha
Wierda, William
LEUKEMIA & LYMPHOMA, 2023, 64 : S25 - S26
[16] Genomic Evolution and Resistance during Pirtobrutinib Therapy in Covalent BTK-Inhibitor (cBTKi) Pre-Treated Chronic Lymphocytic Leukemia Patients: Updated Analysis from the BRUIN Study
Brown, Jennifer R.
Desikan, Sai Prasad
Nguyen, Bastien
Won, Helen
Tantawy, Shady I.
McNeely, Samuel
Marella, Narasimha
Ebata, Kevin
Woyach, Jennifer A.
Patel, Krish
Tam, Constantine S.
Eyre, Toby A.
Cheah, Chan Y.
Shah, Nirav N.
Ghia, Paolo
Jurczak, Wojciech
Balbas, Minna
Nair, Binoj
Abada, Paolo
Wang, Chunxiao
Wang, Ying
Roeker, Lindsey E.
Gandhi, Varsha
Wierda, William G.
BLOOD, 2023, 142
[17] Pirtobrutinib; A Next Generation; Highly Selective; Non-covalent BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study
Pagel, John M.
Coombs, Catherine C.
Shah, Nirav N.
Lamanna, Nicole
Lech-Maranda, Ewa
Eyre, Toby A.
Woyach, Jennifer A.
Weirda, William G.
Cheah, Chan Y.
Roeker, Lindsey E.
Patel, Manish R.
Fakhri, Bita
Barve, Minal A.
Tam, Constantine
Lewis, David
Gerson, James N.
Alencar, Alvaro J.
Ghia, Paolo
Schuster, Stephen J.
Davids, Matthew S.
Brown, Jennifer R.
Jurczak, Wojciech
Mato, Anthony R.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 168 - 169
[18] Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study
Shah, Nirav N.
Zinzani, Pier Luigi
Wang, Michael L.
Nasta, Sunita D.
Lech-Maranda, Ewa
Ogawa, Yoshiaki
Fakhri, Bita
Kuss, Bryone
Miyashita, Kaname
Patel, Krish
Coombs, Catherine C.
Ma, Shuo
Patel, Manish
Barve, Minal A.
Tessoulin, Benoit
Stathis, Anastasios
Kim, Won Seog
Ennishi, Daisuke
Hashimoto, Daigo
Kojima, Kensuke
Zelenetz, Andrew D.
Cohen, Jonathon B.
Vose, Julie M.
Maddocks, Kami J.
Munir, Talha
Sun, Fangfang
Bian, Faith
Tsai, Donald E.
Abada, Paolo
Cheah, Chan Y.
BLOOD, 2023, 142
[19] Efficacy of Pirtobrutinib in BTK-Inhibitor Pre-treated Relapsed/ Refractory CLL/SLL: Phase 1/2 BRUIN Study Results by Prior BCL2-Inhibitor Therapy
Woyach, Jennifer A.
Brown, Jennifer R.
Ghia, Paolo
Roeker, Lindsey E.
Patel, Krish
Eyre, Toby A.
Munir, Talha
Lech-Maranda, Ewa
Lamanna, Nicole
Tam, Constantine S.
Seymour, John
Shah, Nirav N.
Ujjani, Chaitra
Fahkri, Bita
Coombs, Catherine C.
Flinn, Ian
Patel, Manisha R.
Nasta, Sunita D.
Cohen, Jonathon B.
Alencar, Alvaro J.
Cheah, Chan Y.
Ma, Shuo
Rhoades, Joanna M.
Jagadeesh, Deepa
Zinzani, Pier Luigi
Osterborg, Anders
Izutsu, Koji
Tsai, Donald E.
Abada, Paolo
Balbas, Minna
Ruppert, Amy S.
Li, Jian
Jurczak, Wojciech
Wierda, William G.
Stilgenbauer, Stephan
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 118 - 119
[20] Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Marginal Zone Lymphoma: Results from Phase 1/2 BRUIN Study
Patel, Krish
Vose, Julie M.
Nasta, Sunita D.
Brown, Jennifer R.
Maddocks, Kami J.
Woyach, Jennifer A.
Shah, Nirav N.
Fakhri, Bita
Tessoulin, Benoit
Ma, Shuo
Jagadeesh, Deepa
Lech-Maranda, Ewa
Coombs, Catherine C.
Patel, Manish
Rhodes, Joanna M.
Ujjani, Chaitra S.
Hoffmann, Marc S.
Cheah, Chan Y.
Munir, Talha
Lewis, David
Scarfo, Lydia
Eyre, Toby A.
Alencar, Alvaro J.
Cohen, Jonathon B.
Zelenetz, Andrew D.
Tsai, Donald E.
Li, Mei
Bian, Faith
Abada, Paolo
Zinzani, Pier Luigi
BLOOD, 2023, 142

← 1 2 3 4 5 →